Organon To Open Cambridge, Mass. R&D Facility In Early 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Akzo Nobel plans to integrate its pharmaceutical businesses, Organon and Diosynth, into a single entity called Organon. The restructuring is part of Akzo's focus on short-term issues with its pharma division.